Most-Upgraded StocksMost-UpgradedNASDAQ:REGN Regeneron Pharmaceuticals (REGN) Stock Price, News & Analysis $1,131.50 -19.06 (-1.66%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$1,128.97â–Ľ$1,152.8750-Day Range$1,024.09â–Ľ$1,201.7652-Week Range$769.19â–Ľ$1,211.20Volume616,625 shsAverage Volume468,461 shsMarket Capitalization$124.68 billionP/E Ratio33.43Dividend YieldN/APrice Target$1,108.95 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Regeneron Pharmaceuticals alerts: Email Address Regeneron Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.81 Rating ScoreUpside/Downside2.0% Downside$1,108.95 Price TargetShort InterestBearish1.91% of Shares Sold ShortDividend StrengthN/ASustainability-2.69Upright™ Environmental ScoreNews Sentiment0.70Based on 18 Articles This WeekInsider TradingSelling Shares$22.30 M Sold Last QuarterProj. Earnings Growth7.33%From $37.80 to $40.57 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.90 out of 5 starsMedical Sector185th out of 910 stocksPharmaceutical Preparations Industry75th out of 426 stocks 2.4 Analyst's Opinion Consensus RatingRegeneron Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on 16 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageRegeneron Pharmaceuticals has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Regeneron Pharmaceuticals' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.91% of the outstanding shares of Regeneron Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRegeneron Pharmaceuticals has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Regeneron Pharmaceuticals has recently increased by 4.98%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRegeneron Pharmaceuticals does not currently pay a dividend.Dividend GrowthRegeneron Pharmaceuticals does not have a long track record of dividend growth. Previous Next 2.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRegeneron Pharmaceuticals has received a 8.96% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Aflibercept", "Casirivimab and imdevimab", and "Alirocumab" products. See details.Environmental SustainabilityThe Environmental Impact score for Regeneron Pharmaceuticals is -2.69. Previous Next 3.2 News and Social Media Coverage News SentimentRegeneron Pharmaceuticals has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Regeneron Pharmaceuticals this week, compared to 16 articles on an average week.Search InterestOnly 14 people have searched for REGN on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.MarketBeat Follows17 people have added Regeneron Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 31% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Regeneron Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $22,298,963.00 in company stock.Percentage Held by InsidersOnly 7.48% of the stock of Regeneron Pharmaceuticals is held by insiders.Percentage Held by Institutions83.31% of the stock of Regeneron Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Regeneron Pharmaceuticals' insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Regeneron Pharmaceuticals are expected to grow by 7.33% in the coming year, from $37.80 to $40.57 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Regeneron Pharmaceuticals is 33.43, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.44.Price to Earnings Ratio vs. SectorThe P/E ratio of Regeneron Pharmaceuticals is 33.43, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 112.07.Price to Earnings Growth RatioRegeneron Pharmaceuticals has a PEG Ratio of 3.13. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRegeneron Pharmaceuticals has a P/B Ratio of 4.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Regeneron Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.>> Get Your FREE Wealth Protection Guide << About Regeneron Pharmaceuticals Stock (NASDAQ:REGN)Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.Read More REGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart REGN Stock News HeadlinesAugust 30, 2024 | insidertrades.comInsider Selling: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) CFO Sells 5,680 Shares of StockAugust 8, 2024 | insidertrades.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) VP Jason Pitofsky Sells 487 SharesSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.September 7 at 5:25 AM | americanbankingnews.comRoyal Bank of Canada Reiterates Outperform Rating for Regeneron Pharmaceuticals (NASDAQ:REGN)September 6 at 2:07 PM | bizjournals.comRegeneron has added hundreds of jobs locally since last yearSeptember 5 at 6:50 PM | seekingalpha.comRegeneron Pharmaceuticals, Inc. (REGN) Wells Fargo 2024 Healthcare Conference (Transcript)September 5 at 1:49 PM | markets.businessinsider.comRBC Capital Keeps Their Buy Rating on Regeneron (REGN)September 5 at 9:10 AM | fool.comPrediction: These 2 Cathie Wood Stocks Could Crush the Market Through 2030September 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.September 4 at 9:17 PM | seekingalpha.comRegeneron Pharmaceuticals, Inc. (REGN) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)September 3, 2024 | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) Lowered to "Buy" at StockNews.comSeptember 1, 2024 | americanbankingnews.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) CFO Sells $6,846,274.40 in StockAugust 28, 2024 | americanbankingnews.comPiper Sandler Boosts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,242.00August 28, 2024 | americanbankingnews.comStockNews.com Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Strong-BuyAugust 28, 2024 | americanbankingnews.comPiper Sandler Raises Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,242.00August 27, 2024 | seekingalpha.comRegeneron Stock: Valuation Now Demands More GrowthAugust 26, 2024 | markets.businessinsider.comRegeneron Pharma: European Commission Approves Ordspono - Quick FactsAugust 26, 2024 | msn.comRegeneron’s cancer therapy gets EU approvalSee More Headlines Receive REGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/01/2024Today9/07/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:REGN CUSIP75886F10 CIK872589 Webwww.regeneron.com Phone(914) 847-7000Fax914-347-2113Employees13,450Year Founded1988Price Target and Rating Average Stock Price Target$1,108.95 High Stock Price Target$1,300.00 Low Stock Price Target$720.00 Potential Upside/Downside-2.0%Consensus RatingModerate Buy Rating Score (0-4)2.81 Research Coverage21 Analysts Profitability EPS (Most Recent Fiscal Year)$33.85 Trailing P/E Ratio33.43 Forward P/E Ratio29.93 P/E Growth3.13Net Income$3.95 billion Net Margins32.04% Pretax Margin34.01% Return on Equity16.80% Return on Assets13.13% Debt Debt-to-Equity Ratio0.10 Current Ratio5.44 Quick Ratio4.62 Sales & Book Value Annual Sales$13.49 billion Price / Sales9.24 Cash Flow$41.33 per share Price / Cash Flow27.38 Book Value$236.63 per share Price / Book4.78Miscellaneous Outstanding Shares110,186,000Free Float101,944,000Market Cap$124.68 billion OptionableOptionable Beta0.12 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Leonard S. Schleifer M.D. (Age 71)Ph.D., Co-Founder, President, CEO & Co-Chairman Comp: $8.18MDr. George D. Yancopoulos M.D. (Age 64)Ph.D., Co-Founder, President, Chief Scientific Officer & Co-Chairman Comp: $7.76MDr. Andrew J. Murphy Ph.D. (Age 65)Executive Vice President of Research Comp: $1.68MMr. Daniel P. Van Plew (Age 51)Executive VP and GM of Industrial Operations & Product Supply Comp: $2.01MMr. Christopher R. Fenimore CPA (Age 53)Senior VP of Finance & CFO Ms. Patrice GiloolySenior Vice President of Quality Assurance & OperationsMr. Bob McCowanSenior VP of IT & Chief Information OfficerMr. Ryan CroweSenior Vice President of Investor Relations & Strategic AnalysisMr. Joseph J. LaRosa (Age 65)Executive VP, General Counsel & Secretary Comp: $1.75MMs. Melissa LoznerSenior VP & Chief Compliance OfficerMore ExecutivesKey CompetitorsAmgenNASDAQ:AMGNVertex PharmaceuticalsNASDAQ:VRTXGilead SciencesNASDAQ:GILDAllerganNYSE:AGNAlexion PharmaceuticalsNASDAQ:ALXNView All CompetitorsInsiders & InstitutionsSanctuary Advisors LLCBought 45,299 shares on 9/5/2024Ownership: 0.041%Christopher R FenimoreSold 5,680 sharesTotal: $6.85 M ($1,205.33/share)Souders Financial AdvisorsBought 762 shares on 8/28/2024Ownership: 0.001%Kestra Investment Management LLCBought 416 shares on 8/28/2024Ownership: 0.000%New Wave Wealth Advisors LLCBought 366 shares on 8/27/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions Should I Buy Regeneron Pharmaceuticals Stock? REGN Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Regeneron Pharmaceuticals, Inc.: Regeneron Pharmaceuticals has shown a 12.3% increase in revenue on a year-over-year basis, indicating growth potential. Equities analysts expect the company to post $37.45 EPS for the current year, suggesting strong earnings performance. Recent institutional investors have been increasing their positions in Regeneron Pharmaceuticals, signaling confidence in the company's future prospects. Multiple analysts have given the stock positive ratings, with a consensus rating of "Moderate Buy" and an average price target of $1,097.05, indicating optimism in the stock's potential. Director Arthur F. Ryan recently sold 100 shares of the company's stock at an average price of $1,059.24, which could be seen as a vote of confidence in the company's performance. Cons Investors should be bearish about investing in Regeneron Pharmaceuticals, Inc. for these reasons: Some analysts have given the stock a sell rating, indicating a potential downside risk. Insiders have sold a total of 17,731 shares of company stock valued at $18,230,142 over the last three months, which could raise concerns about insider sentiment. While the stock has received positive ratings, there is always a level of uncertainty in the biopharmaceutical industry due to regulatory challenges and market competition. The stock price may be influenced by market volatility and macroeconomic factors, impacting short-term returns for investors. Investors should consider conducting thorough research and analysis before making investment decisions in the biopharmaceutical sector. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, August 25, 2024. Please send any questions or comments about these Regeneron Pharmaceuticals pros and cons to contact@marketbeat.com. REGN Stock Analysis - Frequently Asked Questions How have REGN shares performed this year? Regeneron Pharmaceuticals' stock was trading at $878.29 at the beginning of 2024. Since then, REGN shares have increased by 28.8% and is now trading at $1,131.50. View the best growth stocks for 2024 here. How were Regeneron Pharmaceuticals' earnings last quarter? Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced its quarterly earnings results on Thursday, August, 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, beating analysts' consensus estimates of $8.93 by $2.63. The company's revenue for the quarter was up 12.3% compared to the same quarter last year. Read the conference call transcript. What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO? 423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees. Does Regeneron Pharmaceuticals have any subsidiaries? Regeneron Pharmaceuticals subsidiaries include Eastside Campus Holdings LLC, Loop Road Holdings LLC, Old Saw Mill Holdings LLC, OSMR Holdings, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, and others. Who are Regeneron Pharmaceuticals' major shareholders? Top institutional investors of Regeneron Pharmaceuticals include Legal & General Group Plc (0.89%), Bank of New York Mellon Corp (0.78%), American Century Companies Inc. (0.75%) and Dimensional Fund Advisors LP (0.53%). Insiders that own company stock include George Yancopoulos, Leonard S Schleifer, Neil Stahl, Andrew J Murphy, Joseph J Larosa, Robert E Landry, Plew Daniel P Van, Arthur F Ryan, Christopher R Fenimore, Marion Mccourt, Joseph L Goldstein, Jason Pitofsky, Marc Tessier-Lavigne, Christine A Poon, Michael S Brown, Bonnie L Bassler, Huda Y Zoghbi, N Anthony Coles and George L Sing. View institutional ownership trends. How do I buy shares of Regeneron Pharmaceuticals? Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Regeneron Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ) and Walt Disney (DIS). This page (NASDAQ:REGN) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regeneron Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free REGN Stock Alerts